Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04197141

Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionated WPRT in Prostate Cancer

The purpose of this research study is to determine if 5 (five) fractions of external radiotherapy with higher radiation doses per fraction to the pelvis leads to similar results to the standard of care external radiotherapy treatment that is comprised of 25 fractions of external radiotherapy with lower radiation doses per fraction to the pelvis.

This study aims to investigate the impact in quality of life associated with hypofractionated Whole Pelvis Radiotherapy (WPRT) in comparison to conventionally-fractionated WPRT in patients with unfavorable-intermediate and high-risk prostate cancers. This information is valuable as hypofractionated WPRT is a more attractive and convenient treatment approach, and may become the new standard of care if proven to be well-tolerated and effective. Therefore, this study aims to provide a more rational justification for use of hypofractionated WPRT in future larger randomized trials by comparing this strategy with the current standard of care. This study will also provide an initial understanding of the toxicity profile and cancer control associated with hypofractionated WPRT and High Dose Rate Brachytherapy (HDR-BT).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

Tom Baker Cancer Centre, Calgary, Alberta, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 or older
  • Study Informed Consent provided
  • Pathologically proven diagnosis of prostatic adenocarcinoma
  • Unfavorable intermediate risk [with greater than 15% chance of node involvement based on Memorial Sloan Kettering Cancer Center (MSKCC) nomogram https://www.mskcc.org/nomograms/prostate] or high or very-high-risk prostate cancer based on National Comprehensive Cancer Network (NCCN) classification [Prostatic Specific Antigen (PSA) > 20 ng/mL or clinical cT3a or cT3b or Gleason 8-10]
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
  • No prior history of pelvic irradiation, brachytherapy, cryosurgery, High-Intensity Focused Ultrasound (HIFU), Transurethral Resection of the Prostate (TURP) or radical prostatectomy

Exclusion criteria

  • Presence of nodal or distant metastasis, as confirmed by Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT) of the chest/abdomen/pelvis and bone scan within 45 days of randomization
  • Plan for adjuvant docetaxel post-radiotherapy
  • Serious medical comorbidities or other contraindications to HDR-BT
  • Presence of inflammatory bowel disease
  • Presence of connective tissue disease
  • Medically unfit for general anesthesia
  • Unable or unwilling to complete questionnaires

Treatment and study plan

Conventionally-fractionated WPRT

Radiation

Total dose: 45 Gy in 25 fractions WPRT

Hypofractionated WPRT

Radiation

Total dose: 25 Gy in 5 fractions WPRT

Primary outcomes

  1. Quality of Life (QOL) - late bowel function as measured by the EPIC questionnaire

    Time frame: I year post treatment (approximately 3 years and 2 months)

    Late bowel function as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) sub-domain approximately 1 year after the end of treatment. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

Secondary outcomes

  1. Quality of Life - acute urinary and sexual QOL as measured by the EPIC questionnaire

    Time frame: 6 weeks post treatment (approximately 2 years and 3 months)

    Acute urinary and sexual QOL as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) urinary and sexual domains. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

  2. Quality of Life - acute bowel toxicity as measured by the EPIC questionnaire

    Time frame: 6 weeks post treatment (approximately 2 years and 3 months)

    Acute bowel function as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) approximately 6 weeks after the end of treatment. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

  3. Quality of Life - late bowel bother as measured by the EPIC questionnaire

    Time frame: I year post treatment (approximately 3 years and 2 months)

    Late bowel bother as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) sub-domain approximately 1 year after the end of treatment. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

  4. Quality of Life - late urinary and sexual QOL as measured by the EPIC questionnaire

    Time frame: I year post treatment (approximately 3 years and 2 months)

    Late urinary and sexual QOL as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC). The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

  5. International Prostate Symptom Score (IPSS)

    Time frame: 6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)

    International Prostate Symptom Score (IPSS) as reported by the patient at 6 weeks, 1 year, and 2 years post treatment. The IPSS is a tool used for monitoring symptoms of prostate enlargement (benign prostatic hyperplasia). There are 7 questions related to urinary function. Responses are on a scale from 0 (best) to 5 (worst). Responses are added to come up with a total score, measuring if the patient is mildly symptomatic, moderately symptomatic, or severely symptomatic. There is 1 quality of life question related to urinary symptoms. Responses are on a scale from 0 (best) to 6 (worst).

  6. Toxicity - urinary, bowel, and sexual as measured by CTCAE version 4.0

    Time frame: 6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)

    Urinary, bowel, and sexual toxicity will be measured by the Common Terminology Criteria for Adverse Events (CTCAE) version 4, at 6 weeks, 1 year, and 2 years post treatment.

  7. Prostatic Specific Antigen (PSA) curve

    Time frame: 4 years post treatment (approximately 6 years and 2 months)

    PSA curve at 4 years post-treatment.

  8. Prostatic Specific Antigen (PSA) Nadir

    Time frame: 4 years post treatment (approximately 6 years and 2 months)

    PSA nadir at 4 years post-treatment.

  9. Cost Effectiveness of Hypofractionated WPRT

    Time frame: End of study (approximately 7 years and 2 months)

    Cost effectiveness analysis of the hypofractionated arm in comparison to the conventionally fractionated treatment arm.

  10. Overall Survival

    Time frame: End of study (approximately 7 years and 2 months)

    The time from randomization to death from any cause.

  11. Biochemical Failure-Free Survival

    Time frame: End of study (approximately 7 years and 2 months)

    The time from randomization to biochemical failure (based on the Phoenix definition) or death from any cause, whichever occurs first.

  12. Freedom from Local Failure

    Time frame: End of study (approximately 7 years and 2 months)

    The time from randomization to first local failure.

  13. Freedom from Regional Failure

    Time frame: End of study (approximately 7 years and 2 months)

    The time from randomization to first regional failure.

  14. Androgen Deprivation Therapy Free Survival

    Time frame: End of study (approximately 7 years and 2 months)

    The time from randomization to start of salvage ADT, death or last follow-up.

  15. Metastasis Free Survival

    Time frame: End of study (approximately 7 years and 2 months)

    The time from randomization to development of metastasis, death or last follow-up.

  16. Prostate Cancer Free Survival

    Time frame: End of study (approximately 7 years and 2 months)

    The time from randomization to death attributed to prostate cancer.

Sponsors and collaborators

Lead sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Other

Collaborators

  • AbbVie
  • Canadian Association of Radiation Oncology

Registry information

Official study title

Is Hypofractionated Whole-Pelvis Radiotherapy (WPRT) as Well Tolerated as Conventionally-Fractionated WPRT in Prostate Cancer Patients? (HOPE-Trial)

Acronym: HOPE

Important dates

Study start
2020
Primary completion
2024
Study completion
2027
First posted
Dec 12, 2019
Registry last updated
Aug 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.